Alfredo Romano

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial

David Goldstein, Robert H. El-Maraghi, Pascal Hammel et al. · JNCI Journal of the National Cancer Institute · 2015 · 663 citations

Medicine, Oncology, Pharmacology +14

Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly <i>nab-</i>Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer

Josep Tabernero, E. Gabriela Chiorean, Jeffrey R. Infante et al. · The Oncologist · 2015 · 142 citations · Full text

Medicine, Oncology, Pharmacology +17

SPARC Expression Did Not Predict Efficacy of <i>nab</i> -Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial

Manuel Hidalgo, Carlos Plaza, Mónica Musteanu et al. · Clinical Cancer Research · 2015 · 131 citations · Full text

Medicine, Oncology, Pharmacology +12

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer

E. Gabriela Chiorean, Daniel D. Von Hoff, Josep Tabernero et al. · British Journal of Cancer · 2016 · 90 citations · Full text

Medicine, Oncology, Pharmacology +14

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial

Werner Scheithauer, Ramesh K. Ramanathan, Malcolm J. Moore et al. · Journal of Gastrointestinal Oncology · 2016 · 65 citations · Full text

Medicine, Oncology, Pharmacology +17